Research
研究内容
[最終更新日 : 2021年1月20日]
研究内容
国立がん研究センター中央病院 腫瘍内科では薬剤開発の早期から治療開発参加し、数多くの企業治験及び医師主導治験を行ってまいりました。また、がんの病態に関する臨床研究、薬物療法の効果・副作用に関する基礎・臨床研究、基礎と臨床との橋渡し研究を通して、新規の医師主導治験の企画・立案を行っています。
世界をリードするがん治療開発
第１相治験から第３相治験まで幅広いフェーズの治療開発を行っております。企業が主導する治験だけでなく、当科が主導して企業の協力のもと行う医師主導治験も多数実績があります。第１相治験は先端医療科との協力のもと新規抗がん剤開発に取り組んでおります。
第１相、２相といった早期の治験の実施施設は限られておりますが、当科では乳がん、婦人科がん、肉腫やその他の希少がんなどの第１相治験の拡大コホートや第２相治験に参加し、最近は抗体薬物複合体などの新たなタイプの薬剤が第３相治験に移行し、承認を得ております。
JCOGなど国内臨床グループの臨床研究やグローバル共同試験にも積極的に参画しています。未来の薬物療法開発を目指して、その基礎となる研究も研究所や企業と協同し行っています。
最近の当科の医師主導治験
当院の治験全体の情報は当院ＨＰをご参照ください。
医師主導治験とは:これまで、医薬品開発は製薬企業のみが行ってきましたが、2003年7月から医師、または歯科医師も医薬品開発にかかわることが認められ、治験を企画して行うことができるようになりました。
医師が自ら治験を行うことを医師主導治験といい、製薬企業が開発しにくい分野などの医薬品開発を推進することが期待されています。乳がんなどの患者さんの多いがん以外にも、企業が治験を行うことが少ない希少がんまで複数の医師主導治験を当科では企画、実施しております。
PATHWAY Trial （HR陽性/HER2陰性進行・転移性乳癌対象の国際第Ⅲ相試験）及び付随研究
https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000034267
STATICE 試験（HER2：1+以上子宮癌肉腫に対するDS-8201aの医師主導治験）及び付随研究
https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000033713
切除不能胞巣状軟部肉腫に対するアテゾリズマブ療法の多施設共同第II相医師主導治験
https://rctportal.niph.go.jp/s/detail/jr?trial_id=jRCT2031200041
治験以外の臨床研究や基礎研究
日本、世界のがん患者のために様々な先進的な取り組みを行っています。研究所、国内外の施設、企業らと協同しながら、若手医師も積極的に参加して成果を出ています。
希少がんの遺伝子プロファイリングと標的治療に関する前向きレジストリ臨床研究 (MASTER KEY Project）
転移再発トリプルネガティブ乳がん新規薬剤導入後予後とバイオマーカー検討：多施設共同前向き観察研究
乳がん患者さんに対するパルボシクリブのPK/PD/PGxに基づく有効性・安全性予測に関する探索的研究
婦人科がんにおけるHER3発現に関する探索的研究
希少がんにおけるバイオマーカーの探索的研究・血中miRNA発現量による診断・治療効果予測研究
乳がんにおける腫瘍増殖や転移および/または治療効果に関するバイオマーカーの探索的研究
婦人科がんにおける腫瘍増殖や転移および/または治療効果に関するバイオマーカーの探索的研究
リキッドバイオプシー研究
PDX研究
その他若手医師からの臨床研究や症例報告多数
雑誌論文（欧文）
| Shiino S, Matsuzaki J, Shimomura A, Kawauchi J, Takizawa S, Sakamoto H, Aoki Y, Yoshida M, Tamura K, Kato K, Kinoshita T, Kitagawa Y, Ochiya T. Serum miRNA-based prediction of axillary lymph node metastasis in breast cancer. Clin CancerRes 25,1817-1827, 2019. | Original Article |
|---|---|
| Mehnert JM, Varga A, Brose MS, Aggarwal RR, Lin CC, Prawira A, de Braud F, Tamura K, Doi T, Piha-Paul SA, Gilbert J, Saraf S, Thanigaimani P, Cheng JD, Keam B. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer. BMC Cancer. 19: 196. doi: 10.1186/s12885-019-5380-3, 2019 | Original Article |
| Noguchi E, Tamura K, Hattori M, Horiguchi J, Sato N, Kanatani K, Matsunaga K, Iwata H, Fujiwara Y. Trastuzumab emtansine plus pertuzumab in Japanese patients with HER2-positive metastatic breast cancer: a phase Ib study. Breast Cancer. 26: 39-46, 2019 | Original Article |
| Tanaka R, Yonemori K, Hirakawa A, Kinoshita F, Kobayashi Y, Yamazaki N, Fujimoto M, Tamura K, Fujiwara Y. Anticancer agent-Induced life-threatening skin toxicities: A database study of spontaneous reporting data. Oncologist. 24: 266-272, 2019 | Original Article |
| Takahashi K, Yunokawa M, Sasada S, Takehara Y, Miyasaka N, Kato T, Tamura K. A novel prediction score for predicting the baseline risk of recurrence of stage I-II endometrial carcinoma. J Gynecol Oncol. 30: e8. doi: 10.3802/jgo. 2019.30.e8, 2019 | Original Article |
| Hironaka-Mitsuhashi A, Tsuda H, Yoshida M, Shimizu C, Asaga S, Hojo T, Tamura K, Kinoshita T, Ushijima T, Hiraoka N, Fujiwara Y. Invasive breast cancers in adolescent and young adult women show more aggressive immunohistochemical and clinical features than those in women aged 40-44 years. Breast Cancer. 26: 386-396, 2019 | Original Article |
| Yonemori K, Shimomura A, Yasojima H, Masuda N, Aogi K, Takahashi M, Naito Y, Shimizu S, Nakamura R, Hashimoto J, Yamamoto H, Hirakawa A, Michimae H, Hamada A, Yoshida T, Sukigara T, Tamura K, Fujiwara Y. A phase I/II trial of olaparib tablet in combination with eribulin in Japanese patients with advanced or metastatic triple-negative breast cancer previously treated with anthracyclines and taxanes. Eur J Cancer. 109: 84-91, 2019 | Original Article |
| Sato J, Shimoi T, Shimomura A, Noguchi E, Kodaira M, Yunokawa M, Yonemori K, Shimizu C, Fujiwara Y, Yoshida M, Tamura K. The incidence of nonmalignant diseases among patients with suspected carcinoma of unknown primary site. Intern Med. 58: 1423-1428, 2019 | Original Article |
| Noda-Narita S, Shimomura A, Kawachi A, Sumiyoshi-Okuma H, Sudo K, Shimoi T, Noguchi E, Yonemori K, Shimizu C, Fujiwara Y, Tamura K. Comparison of the efficacy of trastuzumab emtansine between patients with metastatic human epidermal growth factor receptor 2-positive breast cancers previously treated with combination trastuzumab and pertuzumab and with trastuzumab only in Japanese population. Breast Cancer. 26: 492-498, 2019 | Original Article |
| Yuda S, Shimizu C, Yoshida M, Shiino S, Kinoshita T, Maeshima AM, Tamura K. Biomarker discordance between primary breast cancer and bone or bone marrow metastases. Jpn J Clin Oncol, 49: 426-430, 2019 | Original Article |
| Sunami K, Ichikawa H, Kubo T, Kato M, Fujiwara Y, Shimomura A, Koyama T, Kakishima H, Kitami M, Matsushita H, Furukawa E, Narushima D, Nagai M, Taniguchi H, Motoi N, Sekine S, Maeshima A, Mori T, Watanabe R, Yoshida M, Yoshida A, Yoshida H, Satomi K, Sukeda A, Hashimoto T, Shimizu T, Iwasa S, Yonemori K, Kato K, Morizane C, Ogawa C, Tanabe N, Sugano K, Hiraoka N, Tamura K, Yoshida T, Fujiwara Y, Ochiai A, Yamamoto N, Kohno T. Feasibility and utility of a panel testing for 114 cancer-associated genes in a clinical setting: A hospital-based study. Cancer Sci. 110: 1480-1490, 2019 | Original Article |
| Ito T, Kumagai Y, Itano K, Maruyama T, Tamura K, Kawasaki S, Suzuki T, Murakami Y. Mathematical analysis of gefitinib resistance of lung adenocarcinoma caused by MET amplification. Biochem Biophys Res Commun. 511: 544-550, 2019 | Original Article |
| Turner NC, Alarcón E, Armstrong AC, Philco M, López Chuken YA, Sablin MP, Tamura K, Gómez Villanueva A, Pérez-Fidalgo JA, Cheung SYA, Corcoran C, Cullberg M, Davies BR, de Bruin EC, Foxley A, Lindemann JPO, Maudsley R, Moschetta M, Outhwaite E, Pass M, Rugman P, Schiavon G, Oliveira M. BEECH: A dose-finding run-in followed by a randomised phase 2 study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with oestrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population. Ann Oncol. 30: 774-780, 2019 | Original Article |
| Hirakawa A, Sudo K, Yonemori K, Sadachi R, Kinoshita F, Kobayashi Y, Okuma HS, Kawachi A, Tamura K, Fujiwara Y, Rubinstein L, Takebe N. A comparative study of longitudinal toxicities of cytotoxic drugs, molecularly targeted agents, immunomodulatory drugs, and cancer vaccines. Clin Pharmacol Ther. 106: 803-809, 2019 | Original Article |
| Kobayashi-Kato M, Yunokawa M, Bun S, Miyasaka N, Kato T, Tamura K. Platinum-free interval affects efficacy of following treatment for platinum-refractory or -resistant ovarian cancer. Cancer Chemother Pharmacol. 84: 33-39, 2019 | Original Article |
| Goto K, Fujiwara Y, Isobe T, Chayahara N, Kiyota N, Mukohara T, Tsubata Y, Hotta T, Tamura K, Yamamoto N, Minami H. Pharmacokinetic study of the oral fluorouracil antitumor agent S-1 in patients with impaired renal function. Cancer Sci. 110: 1987-1994, 2019 | Original Article |
| Bun S, Yunokawa M, Ebata T, Kobayashi Kato M, Shimoi T, Kato T, Tamura K. Feasibility of initial treatment in elderly patients with ovarian cancer in Japan: a retrospective study. Int J Clin Oncol. 24: 1111-1118, 2019 | Original Article |
| Tamura K, Tsurutani J, Takahashi S, Iwata H, Krop IE, Redfern C, Sagara Y, Doi T, Park H, Murthy RK, Redman RA, Jikoh T, Lee C, Sugihara M, Shahidi J, Yver A, Modi S. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study. Lancet Oncol. 20: 816-826, 2019 | Original Article |
| Shitara K, Iwata H, Takahashi S, Tamura K, Park H, Modi S, Tsurutani J, Kadowaki S, Yamaguchi K, Iwasa S, Saito K, Fujisaki Y, Sugihara M, Shahidi J, Doi T. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study. Lancet Oncol. 20: 827-836, 2019 | Original Article |
| Yap YS, Lu YS, Tamura K, Lee JE, Ko EY, Park YH, Cao AY, Lin CH, Toi M, Wu J, Lee SC. Insights into breast cancer in the east vs the west: A Review. JAMA Oncol. doi: 10.1001/jamaoncol.2019.0620, 2019 | Original Article |
| Takahashi M, Miki S, Fujimoto K, Fukuoka K, Matsushita Y, Maida Y, Yasukawa M, Hayashi M, Shinkyo R, Kikuchi K, Mukasa A, Nishikawa R, Tamura K, Narita Y, Hamada A, Masutomi K, Ichimura K. Eribulin penetrates brain tumor tissue and prolongs survival of mice harboring intracerebral glioblastoma xenografts. Cancer Sci. 110: 2247-2257, 2019 | Original Article |
| Inagaki C, Shimoi T, Sumiyoshi Okuma H, Kawachi A, Sudo K, Shimomura A, Noguchi E, Kodaira M, Yunokawa M, Yonemori K, Shimizu C, Arakawa A, Ogawa C, Yoshida A, Fujiwara Y, Tamura K. Bone marrow examination in patients with Ewing sarcoma/peripheral primitive neuroectodermal tumor without metastasis based on 18F-fluorodeoxyglucose positron emission tomography/computed tomography. Med Oncol. 36: 58. doi: 10.1007/s12032-019-1279-8, 2019 | Original Article |
| Yazaki S, Yamauchi T, Higashi T. High hepatitis B virus screening rate among patients receiving systemic anticancer treatment in Japan. Int J Clin Oncol. 2020 Mar 21. doi: 10.1007/s10147-020-01655-4. Epub ahead of print. | Original Article |
| Takahashi M, Miki S, Fujimoto K, Fukuoka K, Matsushita Y, Maida Y, Yasukawa M, Hayashi M, Shinkyo R, Kikuchi K, Mukasa A, Nishikawa R, Tamura K, Narita Y, Hamada A, Masutomi K, Ichimura K. Eribulin penetrates brain tumor tissue and prolongs survival of mice harboring intracerebral glioblastoma xenografts. Cancer Sci. 110: 2247-2257, 2019 | Original Article |
| Tamura K, Hasegawa K, Katsumata N, Matsumoto K, Mukai H, Takahashi S, Nomura H, Minami H. Efficacy and safety of nivolumab in Japanese patients with uterine cervical cancer, uterine corpus cancer, or soft tissue sarcoma: a multicenter, open-label phase 2 trial. Cancer Sci. 110: 2894-2904, 2019 | Original Article |
| Shimomura A, Yonemori K, Yoshida M, Yoshida T, Yasojima H, Masuda N, Aogi K, Takahashi M, Naito Y, Shimizu S, Nakamura R, Hamada A, Michimae H, Hashimoto J, Yamamoto H, Kawachi A, Shimizu C, Fujiwara Y, Tamura K. Gene alterations in triple-negative breast cancer patients in a phase I/II study of eribulin and olaparib combination therapy. Transl Oncol. 12: 1386-1394, 2019 | Original Article |
| Kubo M, Kawai M, Kumamaru H, Miyata H, Tamura K, Yoshida M, Ogo E, Nagahashi M, Asaga S, Kojima Y, Kadoya T, Aogi K, Niikura N, Miyashita M, Iijima K, Hayashi N, Yamamoto Y, Imoto S, Jinno H. A population-based recurrence risk management study of patients with pT1 node-negative HER2+ breast cancer: a National Clinical Database study. Breast Cancer Res Treat. 178: 647-656, 2019 | Original Article |
| Yunokawa M, Sasada S, Takehara Y, Takahashi K, Shimoi T, Yonemori K, Ishikawa M, Kato T, Tamura K. Real-world data on initial treatment strategies for older adult patients with endometrial cancer in Japan. Cancer Chemother Pharmacol. 84: 1051-1058, 2019 | Original Article |
| Udagawa C, Horinouchi H, Shiraishi K, Kohno T, Okusaka T, Ueno H, Tamura K, Ohe Y, Zembutsu H. Whole genome sequencing to identify predictive markers for the risk of drug-induced interstitial lung disease. PLoS One. 14: e0223371. doi: 10.1371/journal.pone.0223371, 2019 | Original Article |
| Nakano MH, Udagawa C, Shimo A, Kojima Y, Yoshie R, Zaha H, Abe N, Motonari T, Unesoko M, Tamura K, Shimoi T, Yoshida M, Yoshida T, Sakamoto H, Kato K, Mushiroda T, Tsugawa K, Zembutsu H. A genome-wide association study identifies five novel genetic markers for trastuzumab-Induced cardiotoxicity in japanese population. Biol Pharm Bull. 42: 2045-2053, 2019 | Original Article |
| Sato J, Shimomura A, Kawauchi J, Matsuzaki J, Yamamoto Y, Takizawa S, Sakamoto H, Ohno M, Narita Y, Ochiya T, Tamura K. Brain metastasis-related microRNAs in patients with advanced breast cancer. PLoS One. 14: e0221538. doi: 10.1371/journal.pone.0221538, 2019 | Original Article |
| Kuroda T, Ogiwara H, Sasaki M, Takahashi K, Yoshida H, Kiyokawa T, Sudo K, Tamura K, Kato T, Okamoto A, Kohno T. Therapeutic preferability of gemcitabine for ARID1A-deficient ovarian clear cell carcinoma. Gynecol Oncol. 155: 489-498, 2019 | Original Article |
| Iwata H, Inoue K, Kaneko K, Ito Y, Tsugawa K, Hasegawa A, Nakagawa S, Kuratomi H, Tamura K. Subgroup analysis of japanese patients in a phase 3 study of atezolizumab in advanced triple-negative breast cancer (IMpassion130). Jpn J Clin Oncol. 49: 1083-1091, 2019 | Original Article |
| Yoshida A, Arai Y, Hama N, Chikuta H, Bando Y, Nakano S, Kobayashi E, Shibata J, Fukuhara H, Komiyama M, Watanabe S-I, Tamura K, Kawai A, Shibata T. Expanding the clinicopathologic and molecular spectrum of BCOR-associated sarcomas in adults. Histopathology. doi: 10.1111/his.14023, 2019 | Original Article |
| Tamura K, Imamura CK, Takano T, Saji S, Yamanaka T, Yonemori K, Takahashi M, Tsurutani J, Nishimura R, Sato K, Kitani A, Ueno NT, Mushiroda T, Kubo M, Fujiwara Y, Tanigawara Y. CYP2D6 genotype-guided tamoxifen dosing in hormone receptor-positive metastatic breast cancer (TARGET-1): A randomized, open-label, phase II study. J Clin Oncol. doi: 10.1200/JCO.19.01412, 2019 | Original Article |
| Modi S, Saura C, Yamashita T, Park YH, Kim S-B, Tamura K, Andre F, Iwata H, Ito Y, Tsurutani J, Sohn J, Denduluri N, Perrin C, Aogi K, Tokunaga E, Im S-A, Lee KS, Hurvitz SA, Cortes J, Lee C, Chen S, Zhang L, Shahidi J, Yver A, Krop I, DESTINY-Breast01 Investigators. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. doi: 10.1056/NEJMoa1914510, 2019 | Original Article |
| Noda-Narita S, Shimomura A, Tanabe Y, Kawachi J, Matsuzaki J, Takizawa S, Aoki Y, Shimizu C, Tamura K, Ochiya T. Peripheral neuropathy from paclitaxel: Risk prediction by serum microRNAs. BMJ Support Palliat Care. doi: 10.1136/bmjspcare-2019-001900, 2019 | Original Article |
| Tamura K. Differences of cyclin-dependent kinase 4/6 inhibitor, palbociclib and abemaciclib, in breast cancer. Jpn J Clin Oncol. 49: 993-998, 2019 | Original Article |
| Toki S, Kobayashi E, Yoshida A, Ogura K, Wakai S, Yoshimoto S, Yonemori K, Kawai A. A clinical comparison between dedifferentiated low-grade osteosarcoma and conventional osteosarcoma. Bone Joint J. 101-B:745-752,2019. | Original Article |
| Kawachi A, Yamashita S, Okochi-Takada E, Hirakawa A, Tsuda H, Shimomura A, Kojima Y, Yonemori K, Fujiwara Y, Kinoshita T, Ushijima T, Tamura K. BRCA1 promoter methylation in breast cancer patients is associated with response to olaparib/eribulin combination therapy.Breast Cancer Res Treat. 181:323-329,2020. | Original Article |
| Tanabe Y, Shiraishi S, Hashimoto K, Ikeda K, Nishizawa D, Hasegawa J, Shimomura A, Ozaki Y, Tamura N, Yunokawa M, Yonemori K, Takano T, Kawabata H, Tamura K, Fujiwara Y, Shimizu C. Taxane-induced sensory peripheral neuropathy is associated with an SCN9A single nucleotide polymorphism in Japanese patients. BMC Cancer. 20:325,2020. | Original Article |
| Seo T, Noguchi E, Yoshida M, Mori T, Tanioka M, Sudo K, Shimomura A, Yonemori K, Fujiwara Y, Tamura K. Response to dabrafenib and trametinib of a patient with metaplasticbBreast carcinoma harboring a BRAF V600E mutation. Case Rep Oncol Med. 2020:2518383,2020. | Original Article |
| Kato MK, Yunokawa M, Bun S, Shimoi T, Yonemori K, Miyasaka N, Kato T, Tamura K. Treatment strategies for recurrent ovarian cancer in older adult patients in Japan: a study based on real-world data. J Cancer Res Clin Oncol. 146:1335-1341, 2020. | Original Article |
| Okuma HS, Yonemori K, Narita SN, Sukigara T, Hirakawa A, Shimizu T, Shibata T, Kawai A, Yamamoto N, Nakamura K, Nishida T, Fujiwara Y. MASTER KEY Project: Powering clinical development for rare cancers through a platform trial. Clin Pharmacol Ther. 2020 [Epub ahead of print] | Original Article |
| Yazaki S, Hashimoto J, Yamauchi T, et al. Lower response to trastuzumab emtansine in metastatic breast cancer patients with human epidermal growth factor receptor 2 immunohistochemistry score of 2 and fluorescence in situ hybridization positive compared with immunohistochemistry score of 3: a retrospective study. Anti-Cancer Drugs. in press (2020) | Original Article |
| Frezza AM, Assi T, Lo Vullo S, Ben-Ami E, Dufresne A, Yonemori K, Noguchi E, Siontis B, Ferraro R, Teterycz P, Duffaud F, Ravi V, Vincenzi B, Gelderblom H, Pantaleo MA, Baldi GG, Desar I, Fedenko A, Maki RG, Jones RL, Benjamin RS, Blay JY, Kawai A, Gounder M, Gronchi A, Le Cesne A, Mir O, Czarnecka AM, Schuetze S, Wagner AJ, Adam J, Barisella M, Sbaraglia M, Hornick JL, Meurgey A, Mariani L, Casali PG, Thornton K, Stacchiotti S. Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network. Cancer. 126:98-104,2020. | Original Article |
| Sudo K, Kato K, Matsuzaki J, Takizawa S, Aoki Y, Shoji H, Iwasa S, Honma Y, Takashima A, Sakamoto H, Naka T, Sekine S, Boku N, Ochiya T, Identification of serum microRNAs predicting the response of esophageal squamous-cell carcinoma to nivolumab, JJCO, 2019 Oct, 50(2) | Original Article |
| Sudo K, Kato K, Matsuzaki J, Boku N, Abe S, Saito Y, Daiko H, Takizawa S, Aoki Y, Sakamoto H, Niida S, Takeshita F, Fukuda T, Ochiya T, Development and validation of an Esophageal squamous cell carcinoma detection model by large-scale MicroRNA profiling, JAMA Netw Open. 2019 May; 2(5): e194573. | Original Article |
| Fujiwara H, Ushijima K, Nagao S, Takei Y, Shimada M, Takano M, Yoshino K, Kawano Y, Hirashima Y, Nagase S, Nishio S, Nishikawa T, Ito K, Shoji T, Kimura E, Takano T, Sugiyama T, Kigawa J, Fujiwara K、Suzuki M. A phase II randomized controlled study of pegylated liposomal doxorubicin and carboplatin vs. gemcitabine and carboplatin for platinum-sensitive recurrent ovarian cancer (GOTIC003/intergroup study). Int J Clin Oncol, 24, 10, 1284-1291, 2019 | Original Article |
| Shimoi T, Sagara Y, Hara F, Toyama T, Iwata H. First-line endocrine therapy for postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and meta-analysis. Breast Cancer. doi: 10.1007/s12282-020-01054-7. Epub 2020 Feb 11. | Original Article |
| Kato MK, Yunokawa M, Bun S, Shimoi T, Yonemori K, Miyasaka N, Kato T, Tamura K. Treatment strategies for recurrent ovarian cancer in older adult patients in Japan: a study based on real-world data. J Cancer Res Clin Oncol. doi: 10.1007/s00432-020-03168-z. Epub 2020 Mar 6 | Original Article |
| Okuma HS, Fujiwara Y. Have We Found the Key to Unravel Treatment Development Lags for Rare Cancers?: MASTER KEY Project. Clin Pharmacol Ther. 2019 Sep;106(3):491-492. | Original Article |
| Turnbull AK, Selli C, Martinez-Perez C, Fernando A, Renshaw L, Keys J, Figueroa JD, He X, Tanioka M, Munro | Original Article |
| Watanabe T, Honda T, Totsuka H, Yoshida M, Tanioka M, Shiraishi K, Shimada Y, Arai E, Ushiama M, Tamura K, Yoshida T, Kani Y, Kohno T. Simple prediction model for homologous recombination deficiency in breast cancers in adolescents and young adults. Breast Cancer Research and Treatment, 2020 in press | Original Article |
| Wong KY, Fan C, Tanioka M, Parker JS, Nobel AB, Zeng D, Lin DY, Perou CM. I-Boost: an integrative boosting approach for predicting survival time with multiple genomics platforms. Genome Biol 2019, 7;20(1):52. | Original Article |
| Frezza AM, Assi T, Lo Vullo S, Ben-Ami E, Dufresne A, Yonemori K, Noguchi E, Siontis B, Ferraro R, Teterycz P, Duffaud F, Ravi V, Vincenzi B, Gelderblom H, Pantaleo MA, Baldi GG, Desar I, Fedenko A, Maki RG, Jones RL, Benjamin RS, Blay JY, Kawai A, Gounder M, Gronchi A, Le Cesne A, Mir O, Czarnecka AM, Schuetze S, Wagner AJ, Adam J, Barisella M, Sbaraglia M, Hornick JL, Meurgey A, Mariani L, Casali PG, Thornton K, Stacchiotti S. Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network. Cancer. 126:98-104,2020. | Original Article |
| Li CK, Dalvi R, Yonemori K, Ariffin H, Lyu CJ, Farid M, Gonzales-Santos JRN, Zhou Q, Bielack S, Brugieres L, Blondeel A, Essiaf S, Peccatori FA, Jezdic S, Stark DP, Douillard JY, Saloustros E, Mountzios G. Care of adolescents and young adults with cancer in Asia: results of an ESMO/SIOPE/SIOP Asia survey. ESMO Open. 4:e000467,2019. | Original Article |
雑誌論文（和文）
| 大竹洋平, 須藤一起, 小島勇貴, 瀬尾卓司, 大熊ひとみ, 西川忠曉, 宇野雅哉, 植原貴史, 石川光也, 谷岡真樹, 野口瑛美, 下村昭彦, 米盛勧, 加藤友康, 藤原康弘, 田村研治. 転移再発子宮癌肉腫に対するイホスファミド・パクリタキセル併用療法(IT療法)の有用性に関する後方視的検討, 癌と化学療法, 46巻10号, 1525-1529, 2019 | |
| 下井辰徳. 保険外併用療養制度について 薬剤師が知っておきたい患者申出療養 日本病院薬剤師会雑誌 (1341-8815)56巻2号 Page142-146(2020.02) |
書籍（和文）
| 小島勇貴, 田村研治. 抗悪性腫瘍薬（抗生物質）Pocket Drugs, 470-478, 医学書院, 2019 | |
| 西川忠曉. 改定第2版 婦人科がん薬物療法, 103, MEDICAL VIEW, 2020 | |
| 小島 勇貴、米盛 勧．バイオマーカーによる薬効評価(解説/特集). 別冊・医学のあゆみ Page81-86(2019.9) | |
| 小島 勇貴．下腿浮腫、発赤 -蜂窩織炎を疑っていたら・・・？ Cancer Board Square 5巻3号 p60-63 (2019.10) | |
| 小島 勇貴、田村 研治．NCCオンコパネルについて（特集）. 乳癌の臨床 34巻5号 p395-404 (2019.11) | |
| 鈴木 美記子, 林 光博, 柳下 薫寛, 瀬尾 卓司, 西川 忠曉, 米盛 勧, 田村 研治, 濱田 哲暢. がん治療開発におけるPDXの活用と展望. がん分子標的治療, メディカルレビュー社, 16巻4号, 413-418, 2019 | |
| 下井辰徳. 【総合診療医×がん治療医でハイリスク症状を見抜く-帰してはいけない がん外来患者】(Part2)ケースで学ぶ!がん診療の診断エラー 皮疹 EGFR-TKIによる皮疹を疑っていたら……?Cancer Board Square(2189-6410)5巻3号 Page496-502(2019.10) | |
| 下井辰徳. 【がん治療薬の副作用と支持療法】Financial toxicityとその対策 腫瘍内科 (1881-6568)25巻3号 Page277-286(2020.02) | |
| 下井辰徳. 【これからのがん診療を考える】乳癌 遺伝子パネル検査の現状 クリニシアン (0387-1541)67巻2-3号(2020.03) |